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ORIGINAL

ARTICLE
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Background: Accurate diagnosis of epidermolysis bullosa (EB) has significant implications for prognosis,
management, and genetic counseling.
Objective: To describe diagnostic testing patterns and assess diagnostic concordance of transmission
electron microscopy (TEM), immunofluorescence mapping (IFM), and genetic analysis for EB.
Methods: A retrospective cohort included patients enrolled in the Epidermolysis Bullosa Clinical
Characterization and Outcomes Database from January 1, 2004, to July 8, 2019. Tests concluding the
same EB type (EB simplex, junctional EB, dominant dystrophic EB, and recessive dystrophic EB) were
considered concordant; those concluding different EB types were considered discordant; and those with
nonspecific/nondefinitive results were equivocal.
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Results: A total of 970 diagnostic tests were conducted from 1984 to 2018 in 771 patients. Genetic analyses
were performed chronologically later than IFM or TEM (P \ .001). The likelihood of undergoing genetic
analysis was greater for junctional EB and recessive dystrophic EB, and the same for dominant dystrophic
EB as compared with EB simplex. TEM results in 163 patients were equivocal (55%), concordant (42%), and
discordant (3%). IFM results in 185 patients were equivocal (54%), concordant (42%), and discordant (4%).
Limitations: Retrospective design.
Conclusions: Diagnostic testing has shifted in favor of genetic analysis. TEM and IFM frequently offer
equivocal findings when compared to the specificity afforded by genetic analysis. ( J Am Acad Dermatol
https://doi.org/10.1016/j.jaad.2021.09.065.)
Key words: diagnostic concordance; diagnostic testing; electron microscopy; epidermolysis bullosa;
genetic analysis; genetics; immunofluorescence mapping; laboratory testing; next-generation sequencing.

INTRODUCTION

diagnostic tests play intricate
CAPSULE SUMMARY
roles in resource utilization,
Epidermolysis
bullosa
which ultimately have down(EB) is a heterogeneous
stream effects on patient outgroup of mechanobullous
Limited data are available on the realcomes. Recent guidelines3
disorders resulting from muworld utilization and diagnostic
tations in genes encoding
for implementing various
concordance of laboratory testing for
structural proteins of the
laboratory diagnostic tests
epidermolysis bullosa.
skin.1,2 With thousands of
have weighed the utility of
Our study supports the use of genetic
TEM, IFM, and genetic analknown mutations in at least
analysis for the diagnosis of
ysis, but there remains a need
21 structural genes, the clinepidermolysis bullosa in all cases. In
to establish generalizable
ical spectrum of disease
addition, we suggest genetic analysis be
data to inform EB diagnosis
ranges widely from mild,
considered over skin biopsy for neonates
in practice.
friction-induced blisters of
with skin fragility.
We sought to define the
the extremities to severe,
diagnostic testing patterns in
congenital mucocutaneous
a large cohort of EB patients
fragility accompanied by exand assess the diagnostic concordance of these tests
tracutaneous complications and limited lifespan.3-6
in order to inform management recommendations.
There are 4 major EB types: EB simplex (EBS),
To do so, we utilized a large, contemporary database
junctional EB (JEB), dystrophic EB (DEB), and Kindler
managed by the Epidermolysis Bullosa Clinical
EB (KEB), with over 30 clinical subtypes.3,7
Research Consortium,15 and tracked the utilization
Classification schemes have evolved8,9 to incorporate
biomolecular techniques, including transmission elecand diagnostic concordance of TEM, IFM, and
tron microscopy (TEM),10 immunofluorescence mapgenetic analysis over 4 decades.
ping (IFM),11 and genetic analysis in addition to
clinical phenotype and inheritance patterns.2,7,10,12-14
METHODS
Because distinguishing the major types of EB on
Data source and study population
clinical features alone can be unreliable, especially
The Epidermolysis Bullosa Clinical Characterization
in the neonatal period, rapid and accurate laboratory
and Outcomes Database (EBCCOD) has been
diagnosis is essential.
described previously.15 It constitutes the clinical data
Establishing an accurate and timely diagnosis and
collected contemporaneously and retrospectively from
subtype specification of EB has implications for
20 sites in the United States, Canada, and Mexico. The
prognosis, management, and counseling because
data are housed and managed at the University of
different forms of EB have distinct clinical features
Colorado, Denver. Participation in the database is
and complications that evolve over time. However,
approved by the institutional review board at each
in light of the rarity of EB, limited data are available
participating institution. All patients give written
on variation in real-world diagnostic testing utilizainformed consent/assent upon enrollment.
tion, especially in a large, longitudinal cohort. In
Patients from 18 participating sites who were
particular, the timing and associated costs of
enrolled in the EBCCOD between January 1, 2004,
d

d
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Abbreviations used:
DDEB:
EB:
EBCCOD:
IFM:
IQR:
JEB:
KEB:
NGS:
RDEB:
TEM:

dominant dystrophic epidermolysis
bullosa
epidermolysis bullosa
Epidermolysis Bullosa Clinical Characterization and Outcomes Database
immunofluorescence mapping
interquartile range
junctional epidermolysis bullosa
Kindler epidermolysis bullosa
next-generation sequencing
recessive dystrophic epidermolysis
bullosa
transmission electron microscopy

and July 8, 2019, and who had data available from
diagnostic testing were included. Patients were
initially diagnosed with EB between 1952 and 2018.
Given the mid-year enrollment cutoff, December 31,
2018, was chosen as the cutoff for diagnostic tests (4
tests were reported in 2019, all for patients who were
initially diagnosed with EB prior to 2019).
Type of EB was categorized as EBS, JEB, dominant
dystrophic epidermolysis bullosa (DDEB), and
recessive dystrophic epidermolysis bullosa (RDEB).
A fifth category of unknown/other (including DEB
not otherwise specified and KEB) was included in
the descriptive summary but omitted from statistical
analysis due to the nonspecific diagnostic information and the low number of definitive KEB diagnoses
(n = 4).
Diagnostic testing assessment
Patient data abstracted from the database
included demographics, EB type, and chronology
and results of TEM, IFM, and genetic analysis.
Diagnostic concordance between TEM, IFM, and
genetic analysis was evaluated with genetic analysis
as the reference standard. Tests concluding the same
EB type (eg, EBS, JEB, DDEB, RDEB) were considered to be concordant; those with different EB types
were considered discordant; and those with nonspecific/nondefinitive results, were considered equivocal (eg, EB type could not be definitively concluded
due to the absence of clefting on IFM or TEM; or IFM
or TEM concluded DEB, but could not specify DDEB
vs RDEB). Instances in which genetic analysis was
inconclusive were reported separately.
Statistical analysis
Descriptive statistics were used to describe study
participants and other outcomes of interest. Time-toevent analysis was performed using Cox regression
analysis. A 2-sided P value of \.05 was considered
statistically significant. Statistical analyses were

performed using Excel (Microsoft Corp) and SPSS
Statistics version 26 (IBM).

RESULTS
Patient characteristics
Of 854 patients identified in the EBCCOD during
the study period, 771 (90%) had information available
on the utilization of TEM, IFM, and/or genetic analysis
(Supplementary Fig 1, available via Mendeley at
https://doi.org/10.17632/s9wyv3g982.1). Our study
cohort consisted of 319 (41%) RDEB, 213 (28%)
EBS, 120 (16%) DDEB, 74 (10%) JEB, and 45 (6%)
unknown/other patients (Table I). The yearly composition of the study cohort remained relatively stable
over the study period. The proportion of EBS patients
ranged from 18% to 26%; JEB, 2% to 10%; DDEB, 13%
to 22%; and RDEB, 42% to 56%.
Diagnostic testing patterns and chronology
In total, 970 diagnostic tests were reported in the
34-year period from 1984 to 2018. Genetic analysis
was the most frequently reported diagnostic test (464
of 760; 61%), followed by IFM (285 of 682; 42%) and
TEM (221 of 663; 33%) (Table I). Median age at
testing was greatest for genetic analysis (24.5 months)
compared to TEM (1.8 months) and IFM
(1.0 months). The rate of genetic testing was 67%
(220 of 327) among those born between 2009 and
2019 and 69% (48 of 70) for those born between 2016
and 2019. Genetic mutations in COL7A1, KRT14, and
COL17A1 were most commonly reported in 279, 43,
and 41 patients, respectively (Supplementary Table I,
available via Mendeley at https://doi.org/10.17632/
s9wyv3g982.1). JEB and RDEB patients were more
likely to have received any of TEM, IFM, or genetic
analysis, while EBS patients were less likely to have
had testing ([JEB: OR 3.7; 95% CI, 1.6-8.8], [RDEB: OR
3.0; 95% CI, 2.0-4.5], and [EBS: OR, 0.3; 95% CI, 0.20.4]). No statistically significant relationship between
having any diagnostic test and sex was identified
(P [.2).
Genetic analysis was more frequently performed
on patients ultimately diagnosed with JEB and RDEB
versus EBS (Table I) ([JEB: OR, 2.1; 95% CI, 1.2-3.7],
[RDEB: OR, 2.3; 95% CI, 1.7-3.2], and [EBS: OR, 0.4;
95%, 0.3-0.5]). Median age at testing was greatest for
RDEB patients (48 months; interquartile range [IQR]
4-139 months, P = .01). By Cox regression analysis
accounting for patient sex, the likelihood of undergoing testing was greater for JEB and RDEB, and the
same for DDEB as compared to EBS (Table II).
Fig 1 depicts diagnostic test frequency over time.
Genetic analyses were generally performed chronologically later than IFM or TEM (median [IQR] test
date: April 2014 [May 2010 to March 2016] vs April
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Table I. Patient characteristics and diagnostic testing utilization
EB type*
Demographics

Age at diagnosis, median (IQR),
mo (N = 606)z
Sex, N = 725x
Male
Female
Race, N = 726
American Indian/Alaska Native
Asian
Native Hawaiian/Pacific Islander
Black/African American
White
Middle Eastern/North African
Unknown
Diagnostic testing history
Any, N = 602
Multiple, N = 602
Transmission electron
Microscopy, N = 625
Age at testing, median (IQR),
mo (N = 177) z
Immunofluorescence Mapping,
N = 644
Age at testing, median (IQR),
mo N = 230y
Genetic analysis, N = 715
Age at testing, median (IQR),
mo (N = 390) z

Total*

1.0 (0-4.9)

EBS

JEB

DDEB

RDEB

2.0 (0-12)

1.0 (0-3.9)

1.0 (0-3.0)

0 (0-1.0)

369 (50.9)
356 (49.1)

114 (53.5)
99 (46.5)

36 (48.6)
38 (51.4)

55 (45.8)
65 (54.2)

164 (51.6)
154 (48.4)

5
46
3
48
474
67
83

0
6
1
19
154
8
25

3
5
0
9
34
15
8

1
6
0
14
79
7
13

1
29
2
6
207
37
37

P valuey

\.001
.567

\.001
(0.7)
(6.3)
(0.4)
(6.6)
(65.3)
(9.2)
(11.4)

442 (73.4)
243 (40.4)
214 (34.2)
1.8 (0.3-47.5)
274 (42.5)
1.0 (0.1-16.0)

(0)
(2.8)
(0.5)
(8.9)
(72.3)
(3.8)
(11.7)

(4.1)
(6.8)
(0)
(12.2)
(45.9)
(20.3)
(10.8)

(0.8)
(5)
(0)
(11.7)
(65.8)
(5.8)
(10.8)

92 (53.2)
42 (24.3)
42 (23.5)

53 (89.8)
33 (55.9)
26 (43.3)

73 (70.2)
36 (34.6)
30 (28.6)

4.5 (1.0-19.2)

1.0 (0.2-35.1)

3.0 (1.0-40.9)

56 (29.6)

40 (60.6)

39 (35.8)

3.0 (0.4-13.6)

1.0 (0.2-5.0)

1.4 (0.4-9.2)

(0.3)
(9.1)
(0.6)
(1.9)
(64.9)
(11.6)
(11.6)

224 (84.2)
132 (49.6)
116 (41.3)
1.5 (0.1-53.7)
139 (49.6)
1.0 (0.1-51.0)

\.001
\.001
\.001
.6
\.001
.9

445 (62.2)
91 (44)
56 (75.7)
70 (58.8)
228 (72.4)
\.001
24.5 (3.6-116.7) 18.9 (3.0-62.8) 13.5 (2.2-59.8) 18.1 (4.7-152.9) 48.0 (4.0-138.7)
.01

DDEB, Dominant dystrophic epidermolysis bullosa; EB, epidermolysis bullosa; EBS, epidermolysis bullosa simplex; IQR, interquartile range;
JEB, junctional epidermolysis bullosa; RDEB, recessive dystrophic epidermolysis bullosa.
*Values presented as number (%) except where otherwise stated as median (IQR).
y
P values were determined by chi-square or Kruskal-Wallis between EB types.
z
Prenatal diagnosis or diagnostic testing were excluded for these calculations.
x
Total numbers of patients (N) presented in Table I are specific to the data available for each variable; for example, 725 patients had both a
reported EB type and sex, while 715 had both a reported EB type and genetic analysis status (yes/no).

2011 [October 2006 to February 2014]) and
December 2009 [March 2004 to September 2013],
respectively; (P \.001), while TEM and IFM median
test dates were not appreciably different from one
another (P = .1). The rate of genetic testing per
eligible patient per year surpassed TEM and IFM in
2008. Single-year genetic analysis test frequency was
highest in 2016.
Diagnostic testing concordance
Diagnostic concordance between TEM and genetic
analysis among 163 patients with results available
showed TEM to be largely equivocal (55%) or
concordant (42%) and rarely discordant (3%) with
genetic analysis (Fig 2). Similarly, IFM results among
185 patients with results available were equivocal,
concordant, or discordant in comparison to
genetic analysis in 54%, 42%, and 4%, respectively.

Supplementary Tables II and III (available via
Mendeley at https://doi.org/10.17632/s9wyv3g982.1)
show diagnostic concordance stratified by clinical
subtype. Among the 212 patients with genetic analysis
plus TEM and/or IFM results, there were 8 (4%)
instances of genetic testing that yielded inconclusive
results. Six of these resulted from limited testing of
candidate genes, and in 2 patients, DDEB and RDEB
were unable to be reliably distinguished.
The proportion of equivocal cases within each EB
type was highest in DEB patients for both TEM (85%
DDEB, 67% RDEB, 22% EBS, 20% JEB; P \.001) and
IFM (86% DDEB, 63% RDEB, 28% EBS, 15% JEB;
P \ .001). Supplementary Table IV (available via
Mendeley at https://doi.org/10.17632/s9wyv3g982.1)
and Supplementary Fig 2 (available via Mendeley at
https://doi.org/10.17632/s9wyv3g982.1) summarize
the odds of diagnostic concordance by EB type.
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Table II. Results of Cox regression analyses of time
to test (age, years)
Variable

Any test
JEB vs EBS
DDEB vs EBS
RDEB vs EBS
Male sex (reference,
female)
Transmission electron
microscopy
JEB vs EBS
DDEB vs EBS
RDEB vs EBS
Male sex (reference,
female)
Immunofluorescence
mapping
JEB vs EBS
DDEB vs EBS
RDEB vs EBS
Male sex (reference,
female)
Genetic analysis
JEB vs EBS
DDEB vs EBS
RDEB vs EBS
Male sex (reference,
female)

Hazard
ratio

95% CI

P value

2.339
1.161
1.649
1.247

1.650-3.315
0.842-1.600
1.281-2.122
1.023-1.521

\.001
.363
\.001
.029

2.459
1.112
1.865
1.251

1.456-4.152
0.662-1.868
1.257-2.767
0.926-1.690

.001
.688
.002
.144

2.853
1.281
1.810
1.033

1.836-4.433
0.821-1.998
1.272-2.574
0.795-1.343

\.001
.275
.001
.806

2.162
1.053
1.356
1.178

1.530-3.055
0.758-1.462
1.049-1.753
0.963-1.442

\.001
.760
.020
.111

DDEB, Dominant dystrophic epidermolysis bullosa; EBS,
epidermolysis bullosa simplex; JEB, junctional epidermolysis
bullosa; RDEB, recessive dystrophic epidermolysis bullosa.

DISCUSSION
We present data on a large cohort of patients with
EB that depict real-world utilization of various EB
diagnostic testing modalities over the last 4 decades.
We observed that TEM was the predominant testing
modality in the first half of the study period, 19842001, until IFM gained predominance 20 years after
its introduction in 1981.11,16 IFM has been found to
be more sensitive (97% vs 71%) and specific (100% vs
81%) than TEM using genetic analysis as a reference
standard,17 and is less time-consuming and operator
dependent that TEM.3,18
Ultimately, our results show that diagnostic testing
shifted in favor of genetic analysis over IFM or TEM,
with genetic analyses on average being performed
more recently than IFM or TEM. Sanger sequencing
for EB diagnosis was introduced in 199119,20 and was
typically preceded by IFM and TEM due to sequencing’s prolonged turnaround time and candidate gene
preselection requirements.3 This traditional paradigm is reflected in our data by the younger median
age at TEM and IFM testing versus genetic analysis.

Regardless, the rate of genetic analysis testing20-28
surpassed TEM and IFM in our cohort in 2008.
We observed a peak in genetic analysis testing in
2016 after the introduction of whole-exome
sequencing and next-generation sequencing (NGS)
gene panels for the diagnosis of EB in 2015, which
drastically improved cost and time efficiency.29-33
Superiority of NGS over IFM has been suggested
where a NGS multigene panel established the
diagnosis in 90% of cases compared to 76% with
IFM.33 Moreover, the increasing rate of genetic
analysis for participants born 2009 or later, and
even greater rate for those born after the introduction
of NGS panels for EB in 2016, emphasizes the trend
toward genetic testing.
EB type emerged as a significant factor in the
likelihood of undergoing diagnostic testing. The
increased utilization of diagnostic tests among JEB
and RDEB patients may reflect the increased acuity
and morbidity associated with many forms of
JEB and RDEB that would require increased contact
with the medical system and tertiary EB centers, as
well as precise subtype specification for the management and counseling of these patients.
We also compared diagnostic testing results between TEM, IFM, and genetic analysis, observing that
while TEM and IFM could corroborate a diagnosis,
they frequently offered equivocal findings when
compared to the specificity afforded by genetic
analysis. This was particularly true for forms of
DEB, where DDEB and RDEB both share subepidermal cleavage planes (TEM and IFM), reduced
anchoring fibrils (TEM), and reduced or absent
collagen VII (IFM). IFM has been shown to have
less sensitivity for the diagnosis of EBS and JEB
compared to DEB.34
Of the 4 EB types used in our analysis, the odds of
a concordant TEM test result was highest for EBS
patients, while the odds of a concordant IFM test
result was highest for JEB patients. Although our
analytical framework did not account for the clinical
context underscoring these diagnostic tests, our
results suggest greater utility for TEM with EBS
patients and IFM for JEB patients relative to other
EB types.
The high success rate of genetic analysis we
observed overall (96%) suggests that TEM and IFM,
which require a skin biopsy, should be reserved for
cases in which NGS or Sanger sequencing fail to
establish a definitive diagnosis or provide adequate
prognostic information. For example, in cases in
which genetic testing fails to identify pathogenic
variants in EB-associated genes or identifies variants
of unknown significance, expression or functional
studies may be required in addition to immunostaining
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Fig 1. Timeline of relative diagnostic testing utilization among the EBCCOD: cumulative
proportion of patients with diagnostic testing 1984-2018 normalized to the cumulative number
of patients in the database. EBCCOD, Epidermolysis Bullosa Clinical Characterization and
Outcomes Database; IFM, immunofluorescence mapping; TEM, transmission electron
microscopy.

Fig 2. Diagnostic concordance of transmission electron microscopy or immunofluorescence
mapping compared to genetic analysis stratified by EB type. DDEB, Dominant dystrophic
epidermolysis bullosa; EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis
bullosa; RDEB, recessive dystrophic epidermolysis bullosa.

pattern and intensity data provided by IFM.3
Additionally, in instances where severe JEB is suspected in a neonate, tandem genetic testing and IFM
would contribute to rapid diagnosis and tailored
management.

While an in-depth analysis of the factors contributing to absence of a genetic diagnosis in 39% of our
cohort is outside the scope of this study, likely
contributors have historically included limited availability, prohibitive cost, and prolonged turnaround
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time of genetic analysis. Care of EB in general has
been shown to pose a high financial burden on
patients and caregivers in the United States,35 which
lacks the centralized health system and broad insurance coverage for genetic testing that we imagine has
facilitated the high rates of genetic testing reported in
another registry.36 The lag between observation of
clinical signs and subsequent confirmatory testing,
particularly genetic analysis, has the potential for
significant ramifications for patient outcomes.15
Current guidelines recommend tandem genetic
analysis and skin biopsy for IFM for neonates with
skin fragility in order to inform neonatal management within hours to days as opposed to days to
weeks using genetic analysis alone.3 However, commercial diagnostic genetic analysis capabilities have
since advanced following the publication of these
guidelines. In fact, some US-based genetic testing
services offer turnaround times as short as 1 week for
whole-exome sequencing in emergent cases.37-39
Moreover, in a survey of several commercial NGS
panels for EB, self-pay costs have decreased by 13%
to 51% to as low as $890 between 2018 and 2021.40-43
We anticipate that as commercially available clinical
genetic analysis capabilities continue to advance44
and reimbursement for diagnostic testing equilibrates with consensus- and evidence-driven best
practices, EB nosology and diagnostic algorithms
will continue to be refined. Formal quantitative costanalysis studies are needed to fully capture the value
of various diagnostic tests, which remains difficult for
a rare congenital disorder in a dynamic genomics
landscape.
In summary, our results demonstrate
increased utilization of genetic testing for EB
and support recent guidelines that EB laboratory
diagnosis should be performed and that genetic
testing is recommended for the diagnosis of EB.3
We concur that genetic analysis allows for the
following: (1) precise diagnosis,7,33,45 (2) prenatal testing and counseling, (3) preimplantation
testing and counseling,46-50 (4) prognostication,
and (5) pathogenetic-directed therapy.5,51
While the EBCCOD is a large, multicenter, longitudinal, and contemporary database of North
American EB patients, our dataset is biased toward
patients who present to the participating specialized
EB centers; eg, toward patients with severe enough
disease to warrant ongoing management and access
to specialized care, but against patients with rapidly
lethal forms of EB. This would explain the relatively
lower number of EBS patients in our cohort than
expected. Furthermore, not all data points of interest
were available for every enrolled participant in the
database, which likely skews toward more recently

enrolled participants. In addition, the lack of granularity in the genetic analysis data precluded comparisons of the various genetic analysis methods,
including whether multiple stages of genetic analysis
were required.
There was great variance in which laboratories
were used for all testing formats, making comparison
of results more difficult. As mentioned above, the
diagnostic concordance schemes may have underestimated the utility of IFM and TEM for DEB because
concordance with genetic analysis frequently
required the differentiation of RDEB and DDEB.
Finally, we cannot draw any direct conclusions about
the accuracy of genetic analysis because it acted as
the reference standard when diagnostic concordance was established with TEM and IFM.

CONCLUSIONS
Our analysis of diagnostic testing for EB in North
America over the past 4 decades revealed a definitive
shift toward genetic analysis over TEM and IFM that
correlated with technological advances in the field.
EB type emerged as a significant factor in the
likelihood of receiving TEM, IFM, or genetic analysis,
with JEB and RDEB most likely to have received
diagnostic laboratory testing. TEM and IFM revealed
equivocal diagnoses in comparison to genetic analysis in more than half of cases, emphasizing the
specificity afforded by genetic analysis. As turnaround time and cost of genetic analysis continue
to improve, we anticipate increased utilization of
genetic analysis for precise diagnosis of EB with
subtype specification for optimal prognostication
and counseling.
We thank the patients who participated in this study. We
thank Kalyani Marathe, MD, MPH for the provision of 1
study patient from Children’s National Hospital,
Washington DC. The following individuals provided
research support for this study: Hanna Fadzeyeva, MS,
MSc (Hospital for Sick Children), Kyla Pagani, BS
(University of Massachusetts), Rachel Lefferdink, MD and
Milie Fang (Northwestern University), Nicola Natsis, MD,
Allison Han, MD, and Jenna Borok, MD (University of
California San Diego), Kristina Derrick, MD and Laura
Uwakwe, MD (State University of New York Downstate
Health Sciences University).
Conflicts of interest

Dr Bruckner serves as an investigator for Fibrocell,
Phoenix Tissue Repair, PROQR/Wings, and Castle Creek
and on an ad hoc advisory board for Castle Creek. Dr Pope
receives research funding from the EB Research
Foundation. Dr Paller serves as an investigator for Castle
Creek and Lenus Pharmaceuticals and has been a consultant with honorarium for Abeona. Dr Levy serves on the
advisory board for Cassiopea, Regeneron; as an

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 16, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

J AM ACAD DERMATOL

8 Phillips et al

investigator for Fibrocell/Castle Creek, Galderma, Janssen,
Pfizer; on the Data Safety and Monitoring Board for Novan;
and as a section editor for UpToDate. Dr Lucky serves as an
investigator for Lenus Pharmaceuticals and Castle Creek
and on the scientific advisory board for EBRP (EB Research
Partnership) and Abeona. Dr Glick serves as an investigator for Lenus Pharmaceuticals. Authors Phillips,
Augsburger, and Peoples and Drs Huang, Kaplan, Khuu,
Tang, Lara-Corrales, Wiss, Levin, Morel, Hook, Eichenfield,
McCuaig, Powell, Castelo-Soccio, Price, Schachner,
Browning, Jahnke, Shwayder, and Bayliss have no conflicts
of interest to declare.
REFERENCES
1. Fine JD. Epidemiology of inherited epidermolysis bullosa
based on incidence and prevalence estimates from the
National Epidermolysis Bullosa Registry. JAMA Dermatol.
2016;152(11):1231-1238.
2. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited
epidermolysis bullosa: updated recommendations on diagnosis
and classification. J Am Acad Dermatol. 2014;70(6):1103-1126.
3. Has C, Liu L, Bolling MC, et al. Clinical practice guidelines for
laboratory diagnosis of epidermolysis bullosa. Br J Dermatol.
2020;182(3):574-592.
4. Has C, Nystr€
om A, Saeidian AH, Bruckner-Tuderman L, Uitto J.
Epidermolysis bullosa: molecular pathology of connective
tissue components in the cutaneous basement membrane
zone. Matrix Biol. 2018;71-72:313-329.
5. Uitto J. Epidermolysis bullosa: diagnostic guidelines in the
laboratory setting. Br J Dermatol. 2020;182(3):526-527.
6. Uitto J, Bruckner-Tuderman L, Christiano AM, et al. Progress
toward treatment and cure of epidermolysis bullosa: summary
of the DEBRA international research symposium EB2015. J
Invest Dermatol. 2016;136(2):352-358.
7. Has C, Bauer JW, Bodemer C, et al. Consensus reclassification
of inherited epidermolysis bullosa and other disorders with
skin fragility. Br J Dermatol. 2020;183(4):614-627.
8. von Hebra F. Pemphigus. In: Aerztlicher Bericht des K. K.
Allgemeinen Krankenhauses zu Wien vom Jahre 1870. Sommer
und Comp; 1870:362-364.
9. Koebner H. Epidermolysis bullosa hereditaria. Dtsch Med
Wochenschr. 1886;12(2):21-22. Article in German.
10. Pearson RW. Studies on the pathogenesis of epidermolysis
bullosa. J Invest Dermatol. 1962;39:551-575.
11. Hintner H, Stingl G, Schuler G, et al. Immunofluorescence
mapping of antigenic determinants within the dermalepidermal junction in the mechanobullous diseases. J Invest
Dermatol. 1981;76(2):113-118.
12. Fine JD, Bauer EA, Briggaman RA, et al. Revised clinical and
laboratory criteria for subtypes of inherited epidermolysis
bullosa. A consensus report by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa
Registry. J Am Acad Dermatol. 1991;24(1):119-135.
13. Fine JD, Eady RA, Bauer EA, et al. Revised classification system
for inherited epidermolysis bullosa: report of the Second
International Consensus Meeting on Diagnosis and Classification of Epidermolysis Bullosa. J Am Acad Dermatol. 2000;42(6):
1051-1066.
14. Fine JD, Eady RA, Bauer EA, et al. The classification of inherited
epidermolysis bullosa (EB): report of the Third International
Consensus Meeting on Diagnosis and Classification of EB. J Am
Acad Dermatol. 2008;58(6):931-950.
15. Feinstein JA, Jambal P, Peoples K, et al. Assessment of the
timing of milestone clinical events in patients with

n 2021

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

epidermolysis bullosa from North America. JAMA Dermatol.
2019;155(2):196-203.
Pohla-Gubo G, Cepeda-Valdes R, Hintner H. Immunofluorescence mapping for the diagnosis of epidermolysis bullosa.
Dermatol Clin. 2010;28(2):201-210. vii, vii.
Yiasemides E, Walton J, Marr P, Villanueva EV, Murrell DF. A
comparative study between transmission electron microscopy
and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. Am J Dermatopathol. 2006;28(5):387-394.
Intong LR, Murrell DF. Inherited epidermolysis bullosa: new
diagnostic criteria and classification. Clin Dermatol. 2012;30(1):
70-77.
Akker PCVD. Dystrophic Epidermolysis Bullosa: Novel Insights
Into the Genotype-Phenotype Correlation and Somatic Mosaicism. Dissertation. University of Groningen; 2013.
Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, Fuchs E.
Point mutations in human keratin 14 genes of epidermolysis
bullosa simplex patients: genetic and functional analyses. Cell.
1991;66(6):1301-1311.
Bonifas JM, Rothman AL, Epstein EH Jr. Epidermolysis bullosa
simplex: evidence in two families for keratin gene abnormalities. Science. 1991;254(5035):1202-1205.
Christiano AM, Greenspan DS, Lee S, Uitto J. Cloning of human
type VII collagen. Complete primary sequence of the alpha
1(VII) chain and identification of intragenic polymorphisms. J
Biol Chem. 1994;269(32):20256-20262.
Darling TN, McGrath JA, Yee C, et al. Premature termination
codons are present on both alleles of the bullous pemphigoid
antigen 2/type XVII collagen gene in five Austrian families with
generalized atrophic benign epidermolysis bullosa. J Invest
Dermatol. 1997;108(4):463-468.
Koss-Harnes D, Jahnsen FL, Wiche G, Søyland E, Brandtzaeg P,
Gedde-Dahl T Jr. Plectin abnormality in epidermolysis bullosa
simplex ogna: non-responsiveness of basal keratinocytes to
some anti-rat plectin antibodies. Exp Dermatol. 1997;6(1):41-48.
McLean WH, Pulkkinen L, Smith FJ, et al. Loss of plectin causes
epidermolysis bullosa with muscular dystrophy: cDNA cloning
and genomic organization. Genes Dev. 1996;10(14):1724-1735.
Pulkkinen L, Christiano AM, Gerecke D, et al. A homozygous
nonsense mutation in the beta 3 chain gene of laminin 5
(LAMB3) in Herlitz junctional epidermolysis bullosa. Genomics.
1994;24(2):357-360.
Ryyn€anen M, Knowlton RG, Parente MG, Chung LC, Chu ML,
Uitto J. Human type VII collagen: genetic linkage of the gene
(COL7A1) on chromosome 3 to dominant dystrophic epidermolysis bullosa. Am J Hum Genet. 1991;49(4):797-803.
Vidal F, Aberdam D, Miquel C, et al. Integrin beta 4 mutations
associated with junctional epidermolysis bullosa with pyloric
atresia. Nat Genet. 1995;10(2):229-234.
Takeichi T, Liu L, Fong K, et al. Whole-exome sequencing
improves mutation detection in a diagnostic epidermolysis
bullosa laboratory. Br J Dermatol. 2015;172(1):94-100.
Tenedini E, Artuso L, Bernardis I, et al. Amplicon-based nextgeneration sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. Br J Dermatol. 2015;
173(3):731-738.
Lucky AW, Dagaonkar N, Lammers K, Husami A, Kissell D,
Zhang K. A comprehensive next-generation sequencing assay
for the diagnosis of epidermolysis bullosa. Pediatr Dermatol.
2018;35(2):188-197.
Vahidnezhad H, Youssefian L, Saeidian AH, et al. Multigene
next-generation sequencing panel identifies pathogenic variants in patients with unknown subtype of epidermolysis
bullosa: subclassification with prognostic implications. J Invest
Dermatol. 2017;137(12):2649-2652.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 16, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

J AM ACAD DERMATOL

Phillips et al 9

VOLUME jj, NUMBER j

33. Has C, K€
usel J, Reimer A, et al. The position of targeted nextgeneration sequencing in epidermolysis bullosa diagnosis.
Acta Derm Venereol. 2018;98(4):437-440.
34. Yenamandra VK, Bhari N, Ray SB, et al. Diagnosis of inherited
epidermolysis bullosa in resource-limited settings: immunohistochemistry revisited. Dermatol (Basel Switzerland). 2017;
233(4):326-332.
35. Gorell ES, Wolstencroft PW, de Souza MP, Murrell DF, Linos E,
Tang JY. Financial burden of epidermolysis bullosa on patients
in the United States. Pediatr Dermatol. 2020;37(6):1198-1201.
36. Baardman R, Yenamandra VK, Duipmans JC, et al. Novel
insights into the epidemiology of epidermolysis bullosa (EB)
from the Dutch EB Registry: EB more common than previously
assumed? J Eur Acad Dermatol Venereol. 2021;35(4):995-1006.
37. XomeDxXpress (WES with a Verbal Result in 7 Days). GeneDx.
Accessed April 29, 2020. https://www.genedx.com/tests/deta
il/xomedxxpress-wes-with-a-verbal-result-in-7-days-830
38. XomeDxXpress. Rapid whole exome sequencing test information sheet. GeneDx, 2017. Accessed April 29, 2020. https://
www.genedx.com/Resources/TIS-Files/TIS-896-TF37-TH78.pdf
39. Gubbels CS, VanNoy GE, Madden JA, et al. Prospective,
phenotype-driven selection of critically ill neonates for rapid
exome sequencing is associated with high diagnostic yield.
Genet Med. 2020;22(4):736-744.
40. Epidermolysis bullosa NGS panel. Connective Tissue Gene
Tests (CTGT). Accessed February 26, 2021. http://ctgt.net/pan
el/epidermolysis-bullosa-ngs-panel
41. Epidermolysis bullosa (EB) XomeDxslice. GeneDx. Accessed
February 26, 2021. https://www.genedx.com/tests/detail/epi
dermolysis-bullosa-eb-xomedx-slice-759
42. EBSeq: epidermolysis bullosa genetic testing by nextgeneration sequencing. Cincinnati Children’s Molecular Genetics Laboratory. Accessed February 26, 2021. https://www.

43.

44.

45.
46.

47.

48.
49.

50.

51.

cincinnatichildrens.org/-/media/cincinnati%20childrens/home/
service/d/diagnostic-labs/molecular-genetics/test-disorder/ebs
eq%20epidermolysis%20bullosa%20test%20information.pdf?
la=en
Epidermolysis bullosa (EBS) and Related Disorders Panel.
Prevention Genetics. Accessed February 26, 2021. https://
www.preventiongenetics.com/testInfo?val=Epidermolysis1Bu
llosa1%28EBS%291and1Related1Disorders1Panel
Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic test
availability and spending: where are we now? Where are we
going? Health Aff (Millwood). 2018;37(5):710-716.
Castiglia D, Zambruno G. Molecular testing in epidermolysis
bullosa. Dermatol Clin. 2010;28(2):223-229. vii, vii-viii.
Fassihi H, Eady RA, Mellerio JE, et al. Prenatal diagnosis for
severe inherited skin disorders: 25 years’ experience. Br J
Dermatol. 2006;154(1):106-113.
Fassihi H, Liu L, Renwick PJ, Braude PR, McGrath JA. Development and successful clinical application of preimplantation
genetic haplotyping for Herlitz junctional epidermolysis bullosa. Br J Dermatol. 2010;162(6):1330-1336.
Fassihi H, McGrath JA. Prenatal diagnosis of epidermolysis
bullosa. Dermatol Clin. 2010;28(2):231-237. viii, viii.
Fassihi H, Renwick PJ, Black C, McGrath JA. Single cell PCR
amplification of microsatellites flanking the COL7A1 gene and
suitability for preimplantation genetic diagnosis of HallopeauSiemens recessive dystrophic epidermolysis bullosa. J Dermatol Sci. 2006;42(3):241-248.
Pfendner EG, Nakano A, Pulkkinen L, Christiano AM, Uitto J.
Prenatal diagnosis for epidermolysis bullosa: a study of 144
consecutive pregnancies at risk. Prenat Diagn. 2003;23(6):447456.
Marinkovich MP, Tang JY. Gene therapy for epidermolysis
bullosa. J Invest Dermatol. 2019;139(6):1221-1226.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 16, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

